Sniffing Out the Problem: A Dive into Management for Chronic Rhinosinusitis with Nasal Polyps

Activity Overview

Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with significant morbidity and negatively impacts quality of life. The good news is that biologic therapies targeting type 2 inflammatory pathways provide additional treatment options for CRSwNP. However, clinicians not only need to accurately diagnose nasal polyps in patients but also recognize the role of the underlying pathology to incorporate biologic agents into treatment regimens when appropriate, as Dr. Joseph K. Han explains.

0.50 CE Credit(s)
Expires: December 25, 2020

Target Audience

The target audience for this activity is US-based allergy-immunology, ENT, and pulmonology clinicians (physicians, NPs, and PAs) who manage patients with chronic rhinosinusitis with nasal polyps (CRSwNP) (and/or comorbid asthma).

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Accurately diagnose patients with type 2 inflammation-driven nasal polyps (chronic rhinosinusitis with nasal polyps [CRSwNP]) who may be eligible for treatment with biologic therapy
  • Describe the underlying pathophysiology of rhinosinusitis-associated nasal polyps and how this may be used to guide selection of novel biologic therapy
  • Evaluate emerging agents for CRSwNP based on their efficacy and safety data

Activity Faculty

han,_joseph_headshot_higher_resolution_small

Joseph K. Han, MD

Professor
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
Eastern Virginia Medical School
Norfolk, VA